Project Grant R01CA294607
Award Date 5/1/26
Completion Date 4/30/31
Dollars Obligated $610K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Durham, NC 27708, USA
Similar Awards
- Federal Project Grant Award Summary Duke University's Office of Research Administration received a $1.88M Project Grant from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396) awarded on September 23, 2025, with a completion date of August 31, 2029. The award supports research on "Integrating Genome-Wide Association Study Data with Single-Cell 'Omics' to Reveal the Cellular Effectors of Glioblastoma Predisposition." This fundamental cancer...
- Federal Grant Award Summary Duke University's Office of Research Administration received a $402,135 Project Grant from the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396) effective May 1, 2026 through April 30, 2029. The award funds development of SCHICAR (Single-Cell Hi-C Integrating Chromatin Accessibility and RNA), a novel single-cell tri-modal platform technology that simultaneously captures three-dimensional (3D) genome interactions, chromatin...
- Federal Project Grant Award Summary Duke University's Office of Research Administration received a $395,846 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), effective April 1, 2026 through March 31, 2031. This award funds research focused on therapeutic targeting of SMARCAL1 (SNF2-related CREBBP-activator protein) as a novel treatment strategy for therapy-resistant gliomas, specifically IDH-mutant astrocytomas that have developed...
- Federal Grant Award Summary Duke University's Office of Research Administration received a $607,157 Project Grant award from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), effective May 1, 2026 through April 30, 2031. This five-year research initiative addresses the urgent clinical need for new molecular targets to treat neuroendocrine prostate cancer (NEPC), an aggressive and lethal subtype with a five-year survival rate below 20%. The research...
- Federal Project Grant Award Summary Duke University received a $302,524 Project Grant from the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398) awarded on September 10, 2025, with a completion date of April 30, 2028. This F32 postdoctoral fellowship award supports research investigating the role of SMARCAL1, an annealing helicase protein, in promoting glioma cell proliferation and suppressing tumor-intrinsic inflammation in alternative lengthening of...
- Federal Project Grant Award Summary Duke University's Office of Research Administration received a $135,993 Project Grant from the National Cancer Institute under the Cancer Research Manpower program (CFDA 93.398) effective December 1, 2025, with completion anticipated by May 31, 2027. The award funds investigative research examining the role of the Abelson (ABL) kinase-regulated hypoxia inducible factor-1 alpha (HIF-1A) and transcriptional co-activator with PDZ-binding motif (TAZ) signaling...
- Federal Grant Award Summary Duke University received a $2.89 million Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) awarded August 1, 2025, with completion scheduled for July 31, 2029. This research project, titled "Understanding and Targeting Epigenetic Regulation of Immune Evasion in Prostate Cancer," will investigate how epigenetic mechanisms—specifically through the TNRC18 protein—regulate immune evasion in...
- Federal Project Grant Award Summary Duke University's Office of Research Administration received a $175,928 Project Grant from the National Cancer Institute under the Cancer Research Manpower program (CFDA 93.398) on January 18, 2026, with a completion date of January 17, 2027. This award supports biomedical research training and investigator-led cancer research addressing mechanisms of lymphatic metastasis in triple-negative breast cancer. The project examines how the small nucleolar RNA...
- Federal Grant Award Summary Duke University's Office of Research Administration received a $415,257 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), effective July 3, 2025, with completion targeted for June 30, 2027. This research initiative focuses on developing novel chimeric antigen receptor (CAR) T-cell therapies by harnessing B cells from patients following stem cell transplantation for hematological malignancies...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $608,558 Project Grant under the Cancer Biology Research program (CFDA 93.396) to the Research Institute at Nationwide Children's Hospital, effective April 2, 2026, through March 31, 2031. This fundamental cancer research initiative aims to advance understanding of high-risk neuroblastoma through the development of clinically relevant immunocompetent mouse models and the identification of metabolic vulnerabilities that can...